Mylan Recalls 15 Batches of Valsartan Globally- for the Treatment of Hypertension
- Mylan has recalled globally- 6 lots of Amlodipine and Valsartan Tablets- USP (including the 5mg/160mg- 10mg/160mg- and 10mg/320mg strengths)- 7 lots of Valsartan Tablets- USP (including 40 mg- 80 mg- 160 mg- and 320 mg strengths) and 2 lots of Valsartan and Hydrochlorothiazide Tablets- USP (320mg/25mg strength) - detected with traces of N-nitrosodiethylamine (NDEA)
- The voluntarly recall is done for the lots of Valsartan- distributed between Mar- 2017 and Nov- 2018. European Union authorities has already ban sales of valsartan few days’ back
- Valsartan is a combination of amlodipine or hydrochlorothiazide indicated for the treatment of high blood pressure- heart failure and in reduction of cardiovascular mortality
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].